GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

This study tests whether a new drug, OBP-301, injected directly into tumors, can make the immunotherapy drug pembrolizumab work better for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is PD-L1-negative or has stopped responding to immunothera…

This study tests a treatment called CT041, which uses a patient's own immune cells (T-cells) that are modified in a lab to target and attack stomach cancer cells. It is for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The tre…

This study tests whether adding a new drug (liposomal irinotecan) to standard chemotherapy before chemoradiation can completely eliminate cancer in people with advanced esophagogastric cancer. About 40 adults with stage T3/4 or node-positive disease will receive the drug combo, t…

This early-stage study tests an experimental drug called PF-08046050 in people with advanced solid tumors that have come back or not improved with standard treatments. The drug is designed to attach to cancer cells and kill them. The main goal is to check safety and find the righ…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will join this study…

This study tests a new drug combination for people with advanced HER2-positive stomach or gastroesophageal junction cancer whose tumors also have a protein called PD-L1. About 840 participants will receive either the experimental treatment (rilvegostomig plus chemotherapy and tra…

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This study is for people with stomach cancer that has spread to the lining of the abdomen. It compares standard chemotherapy given through a vein to the same treatment plus an extra chemotherapy drug (paclitaxel) delivered directly into the belly through a small port. The goal is…

This study tests whether a short course of radiation combined with immunotherapy and chemotherapy can shrink advanced gastroesophageal junction cancer enough to allow surgery. About 88 adults with locally advanced or unresectable disease will participate. The goal is to improve t…

This study tests a new drug, sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly another drug (rilvegostomig) for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. Abou…

This early-phase study tests a powerful mix of five chemotherapy drugs for people with advanced cancers of the pancreas, stomach, bile ducts, or gallbladder that have not been treated yet. The researchers use a genetic test to adjust the dose of one drug (irinotecan) based on how…

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study tests a combination of two or three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that has worsened after or was not tolerated during first-line immunotherapy. The goal is to see if the combi…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This study is testing whether a short course of radiation combined with immunotherapy and chemotherapy before surgery can safely and effectively treat a type of cancer where the stomach meets the esophagus. About 84 adults with locally advanced but removable cancer will receive t…

This study tests an experimental oral drug called zongertinib, which blocks HER2 (a protein that fuels cancer growth). It is given alone or with other standard treatments to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to…

This early-stage study tests whether adding a drug called aldesleukin (IL-2) to standard immunotherapy and chemotherapy can better control stomach cancer that has spread to the abdomen lining. About 15 adults with this condition will receive the combination. The goal is to see if…

This early-phase study tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation therapy to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II or III esophageal adenocarcinoma. The main goal is to find the …

This study tests whether adding tadalafil (a drug often used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. About 10 adults with resectable cancer will take tadalafil alone for two weeks, then combine…

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that has a specific marker (HER2-positive) and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-…

This study is testing a drug called zolbetuximab combined with chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The goal is to see if this combination can help control the disease longer. About 70 participants will be enrolled, an…

This study tests if a shot under the skin works as well as an IV drip for a cancer drug (tislelizumab) combined with chemotherapy in adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 351 participants will recei…

This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors or slow the dise…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…

This study tests a new way to treat stomach cancer that has spread to the lining of the abdomen. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the belly during surgery. The goal is to help patients recover faster and have few…

This study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday medical practice in Germany. It will include about 1,900 adults who are starting their first palliative therapy. The g…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…